NCI CTEP Approved Trials for the Month of April

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

Phase I

PBTC-042: Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors. Pediatric Brain Tumor Consortium; Gururangan, Sridharan. (919) 668-6288

Phase I/II

ADVL1312: A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors. COG Phase 1 Consortium; Cole, Kristina Ann. (267) 426-2285

ADVL1411: A Phase 1/2 Study of BMN 673 (IND# 121510), an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies. COG Phase 1 Consortium; Schafer, Eric Stephen. (832) 825-4241

URCC-13070: Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers. University of Rochester; Mohile, Supriya Gupta. (585) 275-9319

Phase II

9416: A Randomized Phase II Trial of Cisplatin with or Without Wee1 Kinase Inhibitor MK-1775 for First-Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN). University Health Network-Princess Margaret Hospital; Winquist, Eric William. 519-685-6840

Phase III

E2112: A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer. ECOG-ACRIN Cancer Research Group; Connolly, Roisin M. (410) 614-9217

Other Phases

AALL14B4-Q: IRF-4, a Novel Tumor Suppressor in Pediatric BCR-ABL+ B-ALL. Children’s Oncology Group; Abrams, Scott. (716) 845-4375

AAML14B2-Q: Functional Proteomics for Stratification and Therapeutic Targeting of Chemotherapy Resistance in Acute Myeloid Leukemia. Children’s Oncology Group; Kentsis, Alex. (646) 888-2593

AAML14B3-Q: Targeting the STAT Pathway in Leukemia Stem Cells in Acute Myelogenous Leukemia. Children’s Oncology Group; Stevens, Alexandra Mclean. (832) 824-4824

ABTR13B1-Q: B-Lapachone as a Novel Targeted Therapy for Pediatric Cancers. Children’s Oncology Group; Laetsch, Theodore Willis. (214) 648-3896

Pilot Phase

ABTC-1302: Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma. Adult Brain Tumor Consortium; Cloughesy, Timothy Francis. (310) 825-5321

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.”

My high school experience revolved around constantly worrying about my four younger siblings and mom amidst our normal condition—instability.

August 14, 2026

Vol.52 No.32

By Lavonté Saunders

Guest Editorial

From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma

In November 2022, I was 43 years old, healthy, active, and the founding CEO of the publicly traded tech company GitLab.

What are The CheckPoints movin’ and groovin’ to this summer?
Join the journal club with the best bops: We asked SITC’s 13-piece band of medical musicians for the top papers and songs of the summer

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.

August 14, 2026

Vol.52 No.32

By Sara Willa Ernst

Book Review Guest Editorial

From the desk of Kimryn Rathmell: What to read before these beautiful days slip away
My summer reading challenged me to see people, purpose, and complexity in a new way

One of the great pleasures of summer is having more time to read.

August 14, 2026

Vol.52 No.32

By W. Kimryn Rathmell

Guest Editorial

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion

At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer.

August 14, 2026

Vol.52 No.32

By Richard L. Schilsky, H. Kim Lyerly, Thomas R. Fleming and Renzo Canetta

Clinical Guest Editorial

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception.

August 14, 2026

Vol.52 No.32

By Viktor Clark, Sean M. Dozier, AnnaLynn M. Williams, Cynthia M. Rand and Lee A. Kehoe

NCI CTEP Approved Trials for the Month of April

Phase I

Phase I/II

Phase II

Phase III

Other Phases

Pilot Phase

YOU MAY BE INTERESTED IN

I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.”

From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma

What are The CheckPoints movin’ and groovin’ to this summer?
Join the journal club with the best bops: We asked SITC’s 13-piece band of medical musicians for the top papers and songs of the summer

From the desk of Kimryn Rathmell: What to read before these beautiful days slip away
My summer reading challenged me to see people, purpose, and complexity in a new way

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

Renew today!

Subscriber content

Never miss an issue!

Login

NCI CTEP Approved Trials for the Month of April

Phase I

Phase I/II

Phase II

Phase III

Other Phases

Pilot Phase

YOU MAY BE INTERESTED IN

I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncologyMy mother instilled in me: “Never become a product of your circumstances.”

From “default dead” to living the future of cancer careAs founding CEO of GitLab, I went “founder mode” on my osteosarcoma

What are The CheckPoints movin’ and groovin’ to this summer?Join the journal club with the best bops: We asked SITC’s 13-piece band of medical musicians for the top papers and songs of the summer

From the desk of Kimryn Rathmell: What to read before these beautiful days slip awayMy summer reading challenged me to see people, purpose, and complexity in a new way

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and whyDrug development must convene a forum for candid, cross-sector discussion

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical frameworkDevelopers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

Never miss an issue!

Login

I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.”

From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma

What are The CheckPoints movin’ and groovin’ to this summer?
Join the journal club with the best bops: We asked SITC’s 13-piece band of medical musicians for the top papers and songs of the summer

From the desk of Kimryn Rathmell: What to read before these beautiful days slip away
My summer reading challenged me to see people, purpose, and complexity in a new way

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care